Ligand Pharmaceuticals Inc (LGND)
109.86
-0.18
(-0.16%)
USD |
NASDAQ |
Nov 04, 12:56
Ligand Pharmaceuticals Total Liabilities (Quarterly): 91.21M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 91.21M |
| March 31, 2024 | 107.35M |
| December 31, 2023 | 86.30M |
| September 30, 2023 | 101.33M |
| June 30, 2023 | 93.21M |
| March 31, 2023 | 164.76M |
| December 31, 2022 | 165.18M |
| September 30, 2022 | 234.31M |
| June 30, 2022 | 273.92M |
| March 31, 2022 | 311.99M |
| December 31, 2021 | 476.43M |
| September 30, 2021 | 461.59M |
| June 30, 2021 | 469.77M |
| March 31, 2021 | 549.28M |
| December 31, 2020 | 652.76M |
| September 30, 2020 | 549.62M |
| June 30, 2020 | 547.93M |
| March 31, 2020 | 524.02M |
| December 31, 2019 | 727.68M |
| September 30, 2019 | 696.90M |
| June 30, 2019 | 760.38M |
| March 31, 2019 | 834.01M |
| December 31, 2018 | 699.89M |
| September 30, 2018 | 1.406B |
| June 30, 2018 | 1.238B |
| Date | Value |
|---|---|
| March 31, 2018 | 257.49M |
| December 31, 2017 | 252.37M |
| September 30, 2017 | 237.57M |
| June 30, 2017 | 230.62M |
| March 31, 2017 | 230.94M |
| December 31, 2016 | 230.73M |
| September 30, 2016 | 230.47M |
| June 30, 2016 | 224.88M |
| March 31, 2016 | 221.36M |
| December 31, 2015 | 226.15M |
| September 30, 2015 | 229.52M |
| June 30, 2015 | 235.71M |
| March 31, 2015 | 230.83M |
| December 31, 2014 | 233.62M |
| September 30, 2014 | 229.50M |
| June 30, 2014 | 36.76M |
| March 31, 2014 | 40.47M |
| December 31, 2013 | 55.10M |
| September 30, 2013 | 56.86M |
| June 30, 2013 | 60.30M |
| March 31, 2013 | 67.77M |
| December 31, 2012 | 77.78M |
| September 30, 2012 | 76.27M |
| June 30, 2012 | 86.14M |
| March 31, 2012 | 92.56M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
86.30M
Minimum
Dec 2023
727.68M
Maximum
Dec 2019
346.77M
Average
311.99M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 8.116B |
| Agios Pharmaceuticals Inc | 112.55M |
| ADMA Biologics Inc | 188.13M |
| Pieris Pharmaceuticals Inc | 6.346M |
| AnaptysBio Inc | 417.50M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 866.40M |
| Shareholders Equity (Quarterly) | 775.20M |
| Current Ratio | 16.82 |
| Net Debt Paydown Yield | 1.01% |